Skip to main content

Table 1 Patient characteristics

From: Classification of ductal carcinoma in situ by gene expression profiling

In situ samples

Invasive samples

Differentiation

Number (percentage)

Histological grade

Number (percentage)

Well

6 (15%)

1

5 (12.5%)

Intermediately

18 (45%)

2

11 (27.5%)

Poorly

14 (35%)

3

24 (60%)

Good/poor component

1 (2.5%)

  

LCIS

1 (2.5%)

  

IHC

 

IHC

 

ER-positive

28 (70%)a

ER-positive

22 (55%)c

PR-positive

24 (60%)a

PR-positive

19 (47.5%)d

Her2/neu-positive (3+)

12 (30%)b

Her2/neu-positive (3+)

4 (10%)d

p53-positive

11 (27.5%)b

p53-positive

9 (22.5%)d

Tumour detection

   

Palpation

17 (42.5%)

  

Microcalcifications

18 (45%)

  

Others

5 (12.5%)

  

Tumour diameter (mm)

   

Range

10 to 80

  

Median

45

  

Average

42.8

  

Treatment

   

Mastectomy

24 (60%)

  

Breast conserving treatment

6 (15%)

  

Local excision followed by mastectomy

10 (25%)

  
  1. a5% not assessable, b2.5% not assessable, c27.5% not assessable, d30% not assessable. ER, oestrogen receptor; IHC, immunohistochemistry; LCIS, lobular carcinoma in situ; PR, progesterone receptor.